Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinaseXiaoyong Fu, Rachel Schiff, C. Kent Osborne et al.|Breast Cancer Research|2014Cited by 70
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistanceGladys Morrison, Rachel Schiff, Xiaoyong Fu et al.|Breast Cancer Research and Treatment|2014Cited by 61
NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancerRaksha R. Bhat, Meghana V. Trivedi, Hariprasad Thangavel et al.|Scientific Reports|2022Cited by 27
GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancerRaksha R. Bhat, Meghana V. Trivedi, Puja Yadav et al.|Breast Cancer Research and Treatment|2018Cited by 25
A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2‐positive breast cancerNoor Mazin Abdulkareem, Meghana V. Trivedi, Raksha R. Bhat et al.|The FASEB Journal|2021Cited by 25